Global pharma major Novo Nordisk has announced a sweeping strategic partnership with OpenAI aimed at transforming how medicines are discovered, developed, and delivered, in a move that signals one of the most ambitious AI integrations yet in global healthcare.
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations—from early-stage drug discovery to manufacturing, supply chains, and commercial functions. The goal: to accelerate the path from research to treatment, cut development timelines, and unlock new therapies for patients faster than ever before.
“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives,” said Mike Doustdar, president and CEO of Novo Nordisk.
“Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.”
Under the agreement, OpenAI will also support Novo Nordisk in upskilling its global workforce, strengthening AI literacy, and embedding machine learning tools into day-to-day decision-making across research, manufacturing, and commercial teams.
Pilot programmes will launch across R&D, production, and operations, with full integration targeted by the end of 2026.
The partnership is being implemented with strict data governance, human oversight, and compliance safeguards to ensure responsible and ethical use of AI in regulated healthcare environments.
“AI is reshaping industries and in life sciences, it can help people live better, longer lives,” said Sam Altman, CEO of OpenAI. “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”
Novo Nordisk said the deal builds on its existing AI initiatives and broader collaborations with technology partners and research organisations as it pushes to modernise its drug development pipeline and global operations.
_256_275.jpg)
